OVERVIEW

Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease.

Market Listings For Amarin Stock

Amarin is listed on the Nasdaq capital market (ticker: AMRN).

more >>

1-Jul-2009	Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
10-Jun-2009	Amarin Announces Results From Exploratory Phase 2a Study Of EN101 In Myasthenia Gravis
26-May-2009	Amarin Announces $2.6 Million Bridge Financing

Upcoming Events

more >>

There are currently no events scheduled

Investor Relations Contacts

Amarin Corporation plc
First Floor, Block 3, The Oval
Ballsbridge, Dublin 4, Ireland
Darren Cunningham

t: +353 (0) 1 669 9020
f: +353 (0) 1 669 9028
e: investor.relations@amarincorp.com

Company Registrars

Lloyds TSB Registrars,
The Causeway,
Worthing,
West Sussex
BN99 6DA, UK

Citibank,
P.O. Box 43077,
Providence,
RI 02940-5000, USA

This page was last updated on July, 1 2008.

Main Navigation

INVESTOR RELATIONS

Mailing List

INVESTOR RELATIONS

OVERVIEW

Market Listings For Amarin Stock

INVESTOR RELATIONS

Recent News

more >>

Upcoming Events

more >>

INVESTOR RELATIONS

Investor Relations Contacts

Company Registrars

© 2009 Amarin

Web Design by Webtrade.ie